Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

tular Rosacea, while oral medications are prescribed for severe disease. Current oral antibiotic therapies may alleviate symptoms of rosacea, but may present an issue with undesirable side effects). While there are other topical products currently available on the market, there is an opportunity to improve the existing irritation profile for these treatments.

About Omiganan

Cutanea Life Sciences licensed the exclusive worldwide rights for dermatological uses to a novel, cationic, antimicrobial peptide, whose active component is omiganan pentahydrochloride from Migenix Inc., a British Columbia Corporation located in Vancouver, BC, Canada (TSX: MGI; OTC: MGIFF). Omiganan is in development as a topical treatment for papulopustular rosacea and may prevent the inflammatory cascade that is theorized to lead to the signs and symptoms of rosacea. Omiganan topical gel has been evaluated in early stage clinical trials at concentrations of 0.5% and 3.0%, and early and late stage trials at 1.0%. At each of these concentrations and in all trials conducted, omiganan was found to be safe, well tolerated and non-irritating with no evidence of systemic absorption. While cationic antimicrobial peptides, such as Omiganan, are well known for their antimicrobial properties, recent research has shown that they also may play a role in the inflammatory response. Omiganan, in in vitro assays, demonstrated a rapid bactericidal activity against microorganisms that colonize the skin and that may play a role in the pathogenesis of inflammatory lesions.

About Cutanea

Cutanea Life Sciences is an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions. The Company strives to maximize value through flawless execution of strategically designed programs. Its core strategy is to in-license novel, patented, mid- stage treatment candidates for aggr
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Dec. 16 Naurex Inc., a new ... and other CNS disorders based on its novel ... presented at a major medical meeting showed that ... anxiolytic-like activity with no signs of the CNS-related ... NMDA receptor(1). The studies also showed that ...
(Date:12/16/2009)... NEW YORK, Dec. 16 Keryx ... today the initiation of a Phase 3 ... Company,s PI3K/Akt pathway inhibitor, in relapsed / ... entitled, "A Phase 3 Randomized Study to ... Added to the Combination of Bortezomib (Velcade®) ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 1New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 2Parents key in new measure to evaluate language in children with autism 48494 1Parents key in new measure to evaluate language in children with autism 48494 2Parents key in new measure to evaluate language in children with autism 48494 3Pre pregnancy depressed mood may heighten risk for premature birth 8792 1Pre pregnancy depressed mood may heighten risk for premature birth 8792 2Pre pregnancy depressed mood may heighten risk for premature birth 8792 3
... ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical,investigators ... and,1b clinical data from ongoing trials of the ... of the American Society,of Clinical Oncology (ASCO) in ... from the Phase 2 trial of single-agent,AP23573 in ...
... /PRNewswire-FirstCall/ -- Iomai,Corporation today announced that it will ... patch-based needle-free influenza vaccine,before the markets open tomorrow. ... at 8:30 a.m. Eastern Time tomorrow to discuss,the ... the live conference call Friday, May 25, 2007 ...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:12/16/2009)... Quantros, Inc., a leading provider of safety and ... healthcare industry, announces the creation of a new ... industry veteran Michael Tulloch, MBA, as Director of ... company,s new Marlborough, MA office. ,, "The expansion ... Tulloch. "Quantros has been developing software for the ...
(Date:12/16/2009)... What happens when the families of sick and dying ... or for them? How do pediatricians respond to such ... religion and spirituality help some patients and families cope ... is almost always the families and patients who raise ... In the current issue of Southern Medical Journal ...
(Date:12/16/2009)... Dec. 16 Tyco International Ltd. (NYSE: ... of Michael E. Daniels for election to the ... General Meeting on March 10, 2010. ,, ... Global Technology Services group of International Business Machines ... for IBM,s Global Services business operations consisting of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... donates time and money to help clothe children in need. ... ... Florida dry cleaner Dryclean USA Florida , along with Atlantic ... Hope to help clothe children in need by collecting funds ... will begin distributing cards, with delivery of their clean clothes, and ...
Breaking Medicine News(10 mins):Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2
... Internet - , , ANTHEM, Ariz., Dec. 29 ... of its new web site at http://www.mychoicedentist.com and ... Phoenix , Arizona, area is proceeding successfully. "Arizona is ... CEO. "We anticipate expanding this service to almost every major ...
... Now Worth Twenty-Five Thousand Dollars at www.MaxMuscle.com/max-formation/ , ... ... Sports Nutrition is rewarding $25,000 cash to the individual who can ... lean muscle and fitness in 2009., , , , ,Bring Yourself ...
... Critically ill patients frequently have uncertain prognoses, but ... prognostic uncertainty candidly, according to a new study ... Center. , "Our interviews revealed that caregivers ... and just the nature of life," said lead ...
... a timely reminder of the issues surrounding the binge ... people and alcohol, a team lead by Professor Christine ... funded by the Economic and Social Research Council (ESRC) ... Focusing on the role of marketing practices in shaping ...
... Team Sponsored by Land Rover, St. Regis Resort Aspen, National ... Land Rover America,s Polo Cup Team participated in the prestigious ... weekend filled with world class polo and camaraderie on and ... was comprised of John Gobin at 8 goals, (one of ...
... against troublesome complication, study finds , , FRIDAY, Dec. 26 ... before cardiac surgery may lower their chances of having ... on variables such as age and the complexity of ... this condition of confusion following heart surgery. The condition ...
Other Medicine News:Health News:Prime Companies Announces Launch of New Dental Web Site 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 3Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 4Health News:Family members of critically ill patients want to discuss loved ones' uncertain prognoses 2Health News:T'is the season to be jolly? 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: